Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aptevo Therapeutics (APVO) Research & Development (2016 - 2025)

Aptevo Therapeutics' Research & Development history spans 11 years, with the latest figure at $4.0 million for Q3 2025.

  • For Q3 2025, Research & Development rose 30.33% year-over-year to $4.0 million; the TTM value through Sep 2025 reached $14.9 million, up 5.66%, while the annual FY2024 figure was $14.4 million, 15.95% down from the prior year.
  • Research & Development for Q3 2025 was $4.0 million at Aptevo Therapeutics, up from $3.3 million in the prior quarter.
  • Across five years, Research & Development topped out at $5.5 million in Q2 2023 and bottomed at $3.1 million in Q3 2024.
  • The 5-year median for Research & Development is $4.0 million (2025), against an average of $4.2 million.
  • The largest annual shift saw Research & Development soared 41.32% in 2023 before it plummeted 33.3% in 2024.
  • A 5-year view of Research & Development shows it stood at $4.5 million in 2021, then increased by 2.88% to $4.7 million in 2022, then decreased by 23.19% to $3.6 million in 2023, then grew by 8.08% to $3.9 million in 2024, then increased by 4.23% to $4.0 million in 2025.
  • Per Business Quant, the three most recent readings for APVO's Research & Development are $4.0 million (Q3 2025), $3.3 million (Q2 2025), and $3.6 million (Q1 2025).